CDKN2A is altered in 11.23% of malignant solid tumor patients with CDKN2A Loss present in 8.53% of all malignant solid tumor patients [4].

CDKN2A Loss is an inclusion criterion in 14 clinical trials for malignant solid tumor, of which 10 are open and 4 are closed. Of the trials that contain CDKN2A Loss and malignant solid tumor as inclusion criteria, 4 are phase 1 (1 open) and 10 are phase 2 (9 open) [5].

CDKN2A is altered in 24.64% of melanoma patients with CDKN2A Loss present in 21.89% of all melanoma patients [4].

CDKN2A Loss is an inclusion criterion in 5 clinical trials for melanoma, of which 4 are open and 1 is closed. Of the trials that contain CDKN2A Loss and melanoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [5].

CDKN2A is altered in 36.49% of glioblastoma patients with CDKN2A Loss present in 48.72% of all glioblastoma patients [4].

CDKN2A Loss is an inclusion criterion in 4 clinical trials for glioblastoma, of which 2 are open and 2 are closed. Of the trials that contain CDKN2A Loss and glioblastoma as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1 (0 open), and 2 are phase 2 (1 open) [5].

CDKN2A is altered in 23.69% of head and neck squamous cell carcinoma patients with CDKN2A Loss present in 9.06% of all head and neck squamous cell carcinoma patients [4].

CDKN2A Loss is an inclusion criterion in 4 clinical trials for head and neck squamous cell carcinoma, of which 4 are open and 0 are closed. Of the trials that contain CDKN2A Loss and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [5].

CDKN2A is altered in 13.2% of non-small cell lung carcinoma patients with CDKN2A Loss present in 9.05% of all non-small cell lung carcinoma patients [4].

CDKN2A Loss is an inclusion criterion in 4 clinical trials for non-small cell lung carcinoma, of which 3 are open and 1 is closed. Of the trials that contain CDKN2A Loss and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 2 (2 open) [5].

CDKN2A is altered in 4.02% of breast carcinoma patients with CDKN2A Loss present in 2.94% of all breast carcinoma patients [4].

CDKN2A Loss is an inclusion criterion in 4 clinical trials for breast carcinoma, of which 1 is open and 3 are closed. Of the trials that contain CDKN2A Loss and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 2 (1 open) [5].

CDKN2A is altered in 30.73% of malignant glioma patients with CDKN2A Loss present in 41.69% of all malignant glioma patients [4].

CDKN2A Loss is an inclusion criterion in 3 clinical trials for malignant glioma, of which 3 are open and 0 are closed. Of the trials that contain CDKN2A Loss and malignant glioma as inclusion criteria, 3 are early phase 1 (3 open) [5].

CDKN2A is altered in 11.57% of lymphoma patients with CDKN2A Loss present in 11.15% of all lymphoma patients [4].

CDKN2A Loss is an inclusion criterion in 3 clinical trials for lymphoma, of which 1 is open and 2 are closed. Of the trials that contain CDKN2A Loss and lymphoma as inclusion criteria, 3 are phase 1 (1 open) [5].

CDKN2A is altered in 2.49% of colorectal carcinoma patients with CDKN2A Loss present in 1.11% of all colorectal carcinoma patients [4].

CDKN2A Loss is an inclusion criterion in 3 clinical trials for colorectal carcinoma, of which 1 is open and 2 are closed. Of the trials that contain CDKN2A Loss and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (1 open) [5].

CDKN2A is altered in 21.11% of bladder carcinoma patients with CDKN2A Loss present in 19.19% of all bladder carcinoma patients [4].

CDKN2A Loss is an inclusion criterion in 2 clinical trials for bladder carcinoma, of which 1 is open and 1 is closed. Of the trials that contain CDKN2A Loss and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].

CDKN2A is altered in 13.44% of soft tissue sarcoma patients with CDKN2A Loss present in 15.02% of all soft tissue sarcoma patients [4].

CDKN2A Loss is an inclusion criterion in 2 clinical trials for soft tissue sarcoma, of which 2 are open and 0 are closed. Of the trials that contain CDKN2A Loss and soft tissue sarcoma as inclusion criteria, 2 are phase 2 (2 open) [5].

CDKN2A is altered in 30.7% of pancreatic carcinoma patients with CDKN2A Loss present in 13.13% of all pancreatic carcinoma patients [4].

CDKN2A Loss is an inclusion criterion in 2 clinical trials for pancreatic carcinoma, of which 1 is open and 1 is closed. Of the trials that contain CDKN2A Loss and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].

CDKN2A is altered in 11.85% of non-hodgkin lymphoma patients with CDKN2A Loss present in 10.71% of all non-hodgkin lymphoma patients [4].

CDKN2A Loss is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain CDKN2A Loss and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [5].

CDKN2A is altered in 19.72% of adenocarcinoma of the gastroesophageal junction patients with CDKN2A Loss present in 10.7% of all adenocarcinoma of the gastroesophageal junction patients [4].

CDKN2A Loss is an inclusion criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain CDKN2A Loss and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

CDKN2A is altered in 17.99% of head and neck carcinoma patients with CDKN2A Loss present in 9.25% of all head and neck carcinoma patients [4].

CDKN2A Loss is an inclusion criterion in 2 clinical trials for head and neck carcinoma, of which 1 is open and 1 is closed. Of the trials that contain CDKN2A Loss and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].

CDKN2A is altered in 8.87% of gastric adenocarcinoma patients with CDKN2A Loss present in 4.43% of all gastric adenocarcinoma patients [4].

CDKN2A Loss is an inclusion criterion in 2 clinical trials for gastric adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain CDKN2A Loss and gastric adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

CDKN2A is altered in 3.32% of ovarian carcinoma patients with CDKN2A Loss present in 2.9% of all ovarian carcinoma patients [4].

CDKN2A Loss is an inclusion criterion in 2 clinical trials for ovarian carcinoma, of which 1 is open and 1 is closed. Of the trials that contain CDKN2A Loss and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].

CDKN2A is altered in 40.0% of esophageal squamous cell carcinoma patients with CDKN2A Loss present in 32.11% of all esophageal squamous cell carcinoma patients [4].

CDKN2A Loss is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A Loss and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDKN2A is altered in 25.76% of chordoma patients with CDKN2A Loss present in 29.09% of all chordoma patients [4].

CDKN2A Loss is an inclusion criterion in 1 clinical trial for chordoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A Loss and chordoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDKN2A is altered in 30.77% of hypopharyngeal squamous cell carcinoma patients with CDKN2A Loss present in 28.57% of all hypopharyngeal squamous cell carcinoma patients [4].

CDKN2A Loss is an inclusion criterion in 1 clinical trial for hypopharyngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A Loss and hypopharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 3 (1 open) [5].

CDKN2A is altered in 25.0% of dedifferentiated chondrosarcoma patients with CDKN2A Loss present in 25.0% of all dedifferentiated chondrosarcoma patients [4].

CDKN2A Loss is an inclusion criterion in 1 clinical trial for dedifferentiated chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A Loss and dedifferentiated chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDKN2A is altered in 16.27% of anaplastic astrocytoma patients with CDKN2A Loss present in 24.73% of all anaplastic astrocytoma patients [4].

CDKN2A Loss is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN2A Loss and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [5].

CDKN2A is altered in 22.22% of acral lentiginous melanoma patients with CDKN2A Loss present in 23.93% of all acral lentiginous melanoma patients [4].

CDKN2A Loss is an inclusion criterion in 1 clinical trial for acral lentiginous melanoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A Loss and acral lentiginous melanoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDKN2A is altered in 48.57% of pancreatic ductal adenocarcinoma patients with CDKN2A Loss present in 20.0% of all pancreatic ductal adenocarcinoma patients [4].

CDKN2A Loss is an inclusion criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A Loss and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

CDKN2A is altered in 16.38% of osteosarcoma patients with CDKN2A Loss present in 18.34% of all osteosarcoma patients [4].

CDKN2A Loss is an inclusion criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A Loss and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDKN2A is altered in 17.54% of mucosal melanoma patients with CDKN2A Loss present in 17.81% of all mucosal melanoma patients [4].

CDKN2A Loss is an inclusion criterion in 1 clinical trial for mucosal melanoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A Loss and mucosal melanoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDKN2A is altered in 22.3% of gallbladder carcinoma patients with CDKN2A Loss present in 17.17% of all gallbladder carcinoma patients [4].

CDKN2A Loss is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A Loss and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDKN2A is altered in 29.63% of head and neck squamous cell carcinoma of unknown primary patients with CDKN2A Loss present in 14.29% of all head and neck squamous cell carcinoma of unknown primary patients [4].

CDKN2A Loss is an inclusion criterion in 1 clinical trial for head and neck squamous cell carcinoma of unknown primary, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A Loss and head and neck squamous cell carcinoma of unknown primary as inclusion criteria, 1 is phase 3 (1 open) [5].

CDKN2A is altered in 12.31% of sarcoma patients with CDKN2A Loss present in 13.08% of all sarcoma patients [4].

CDKN2A Loss is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN2A Loss and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].

CDKN2A is altered in 10.67% of chondrosarcoma patients with CDKN2A Loss present in 12.73% of all chondrosarcoma patients [4].

CDKN2A Loss is an inclusion criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A Loss and chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDKN2A is altered in 26.84% of esophageal carcinoma patients with CDKN2A Loss present in 12.33% of all esophageal carcinoma patients [4].

CDKN2A Loss is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN2A Loss and esophageal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

CDKN2A is altered in 14.62% of bile duct carcinoma patients with CDKN2A Loss present in 11.84% of all bile duct carcinoma patients [4].

CDKN2A Loss is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A Loss and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDKN2A is altered in 14.62% of cholangiocarcinoma patients with CDKN2A Loss present in 11.84% of all cholangiocarcinoma patients [4].

CDKN2A Loss is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A Loss and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDKN2A is altered in 12.74% of B-cell non-hodgkin lymphoma patients with CDKN2A Loss present in 11.32% of all B-cell non-hodgkin lymphoma patients [4].

CDKN2A Loss is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A Loss and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDKN2A is altered in 12.84% of lung carcinoma patients with CDKN2A Loss present in 8.69% of all lung carcinoma patients [4].

CDKN2A Loss is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A Loss and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDKN2A is altered in 10.52% of cancer patients with CDKN2A Loss present in 8.29% of all cancer patients [4].

CDKN2A Loss is an inclusion criterion in 1 clinical trial for cancer, of which 0 are open and 1 is closed. Of the trial that contains CDKN2A Loss and cancer as inclusion criteria, 1 is phase 2 (0 open) [5].

CDKN2A is altered in 5.47% of meningioma patients with CDKN2A Loss present in 5.76% of all meningioma patients [4].

CDKN2A Loss is an inclusion criterion in 1 clinical trial for meningioma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A Loss and meningioma as inclusion criteria, 1 is early phase 1 (1 open) [5].

CDKN2A is altered in 27.73% of oral cavity squamous cell carcinoma patients with CDKN2A Loss present in 5.72% of all oral cavity squamous cell carcinoma patients [4].

CDKN2A Loss is an inclusion criterion in 1 clinical trial for oral cavity squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A Loss and oral cavity squamous cell carcinoma as inclusion criteria, 1 is phase 3 (1 open) [5].

CDKN2A is altered in 12.81% of oropharyngeal squamous cell carcinoma patients with CDKN2A Loss present in 5.51% of all oropharyngeal squamous cell carcinoma patients [4].

CDKN2A Loss is an inclusion criterion in 1 clinical trial for oropharyngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A Loss and oropharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 3 (1 open) [5].

CDKN2A is altered in 9.12% of gastric carcinoma patients with CDKN2A Loss present in 4.52% of all gastric carcinoma patients [4].

CDKN2A Loss is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN2A Loss and gastric carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

CDKN2A is altered in 3.66% of histiocytic and dendritic cell neoplasm patients with CDKN2A Loss present in 3.43% of all histiocytic and dendritic cell neoplasm patients [4].

CDKN2A Loss is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A Loss and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

CDKN2A is altered in 3.78% of malignant uterine neoplasm patients with CDKN2A Loss present in 2.17% of all malignant uterine neoplasm patients [4].

CDKN2A Loss is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A Loss and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

CDKN2A is altered in 2.19% of prostate carcinoma patients with CDKN2A Loss present in 1.64% of all prostate carcinoma patients [4].

CDKN2A Loss is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A Loss and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

CDKN2A is altered in 3.54% of cervical carcinoma patients with CDKN2A Loss present in 1.5% of all cervical carcinoma patients [4].

CDKN2A Loss is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A Loss and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDKN2A is altered in 0.87% of germ cell tumor patients with CDKN2A Loss present in 0.7% of all germ cell tumor patients [4].

CDKN2A Loss is an inclusion criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains CDKN2A Loss and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) [5].

CDKN2A is altered in 0.4% of multiple myeloma patients with CDKN2A Loss present in 0.49% of all multiple myeloma patients [4].

CDKN2A Loss is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A Loss and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDKN2A Loss is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A Loss and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDKN2A Loss is an inclusion criterion in 1 clinical trial for laryngeal small cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A Loss and laryngeal small cell carcinoma as inclusion criteria, 1 is phase 3 (1 open) [5].